Popular GLP- 1 medications made use of for weight management and kind 2 diabetic issues (such as Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, and Trulicity) have actually been linked to an unanticipated problem including fingernails. An international study discovered that people taking these medicines were more than four times as most likely to report nail detachment, a problem in which the nail divides from the skin below it.
Scientists located that 39 % of GLP- 1 customers experienced nail detachment, compared with simply 9 % of people who had never ever taken the drugs. Toenail staining was also substantially extra typical, and two-thirds (66 %) of individuals reported at the very least one nail disorder.
The findings, provided at the European Academy of Dermatology and Venereology (EADV) Congress 2026, originated from the initial controlled study to check out the feasible connection between GLP- 1 medicines and nail wellness.
Unexpected Nail Issues Amongst GLP- 1 Customers
GLP- 1 receptor agonists have actually come to be significantly preferred for taking care of obesity and type 2 diabetes mellitus. These drugs act upon a hormonal agent signaling system that aids manage blood sugar level and cravings, making them efficient tools for enhancing metabolic health and wellness and supporting fat burning.
Nonetheless, scientists are still exploring their possible effects on various other components of the body. Till just recently, information about nail adjustments during GLP- 1 therapy came primarily from individual records of feasible adverse reactions, rather than regulated contrasts.
To examine the connection, scientists examined 575 people using GLP- 1 medications and contrasted them with 1, 329 people that had type 2 diabetes mellitus and/or obesity however had actually never ever utilized the drugs. Participants were hired from France, the United States, Brazil, and Mexico.
The outcomes disclosed a consistent pattern. Overall, 66 % of GLP- 1 customers reported a minimum of one nail problem, compared to 53 % of the control team. Toenail staining showed a specifically large distinction, influencing 46 % of individuals versus 17 % of nonusers.
Toenail detachment was much more striking, with records greater than 4 times as usual among those taking GLP- 1 drugs.
Weight Reduction Alone Might Not Describe the Toenail Changes
One crucial inquiry was whether the nail issues could merely be related to weight loss, instead of to the drugs themselves. Quick adjustments in body weight can impact nourishment and other physical processes, possibly influencing nail and hair wellness.
Nonetheless, the scientists located that weight loss did not totally account for the distinctions. Even when they limited their evaluation to participants that had reduced weight, GLP- 1 users continued to report considerably more nail issues than those that had actually not made use of the medications.
“Previously, nail changes related to GLP- 1 treatments had basically been anecdotal,” claimed research study writer Dr. Charles Taïeb. “Our searchings for reveal a clear association, but they likewise highlight an important point: not whatever that takes place throughout GLP- 1 treatment is always brought on by the treatment itself.”
The researchers stressed that their findings do not show that GLP- 1 drugs trigger nail problems. Around fifty percent of the drug users stated they had actually experienced nail problems even before starting treatment.
When the researchers accounted for existing skin problem and nutritional deficiencies, some of the distinctions in between the teams became smaller. Nonetheless, nail detachment and staining stayed approximately 2 to 3 times extra usual amongst GLP- 1 individuals after these adjustments.
Scientists Likewise Discover Higher Prices of Loss Of Hair and Scalp Problems
The unexpected findings were not limited to fingernails.
A companion research study checking out the very same participants recognized considerable distinctions in hair and scalp wellness among individuals taking GLP- 1 medicines.
Half of GLP- 1 users reported uncommon loss of hair, compared to 34 % of nonusers. Decreased hair quantity or thickness was additionally considerably even more typical, influencing 42 % of users versus 19 % of the control team.
Scientist furthermore examined hair loss that began after therapy began. This was reported by 26 % of GLP- 1 customers, compared to 12 % of nonusers, making it more than twice as usual in the drug team.
Scalp redness was roughly three times more frequent amongst GLP- 1 individuals.
A specifically intriguing searching for was that loss of hair seldom appeared on its own. A lot of individuals who reported losing likewise experienced various other scalp symptoms, consisting of itching, redness or flaking skin.
These going along with signs increased the possibility that inflammation could be adding to the changes, as opposed to the loss of hair being clarified totally by fast weight reduction.
“This recommends that what is taking place on the scalp might go beyond the classic losing seen after rapid weight loss and entail an inflammatory element,” explained research study writer Dr. Bruno Halioua. “Scalp inflammation was the policy rather than the exception, which clinicians do not presently search for and which may be treatable. Taken together, our findings recommend that elements beyond weight loss alone might add to the hair, scalp and nail changes observed amongst GLP- 1 customers.”
What the Findings Mean for People Taking GLP- 1 Medications
In spite of the fairly high regularity of reported signs and symptoms, the scientists emphasized that the findings should motivate awareness rather than alarm.
“These changes are frequent, normally benign, and are not a reason to quit an effective treatment on one’s very own initiative,” he said. “Any person who notifications hair losing, a scratchy or red scalp or nail changes must state it to their doctor instead of stop treatment.”
There are additionally essential restrictions to consider. Both investigations were cross-sectional researches, indicating they took a look at individuals’ experiences without following them gradually to establish exactly how signs and symptoms developed. The findings likewise relied on signs and symptoms reported by individuals as opposed to standardized clinical examinations.
As a result, the studies can expose patterns and organizations, however they can not figure out whether GLP- 1 medicines straight created the reported nail, hair, or scalp issues.
To examine these inquiries more thoroughly, the research group intends to conduct potential researches that follow people from the beginning of therapy. These investigations will certainly consist of standard skin, hair and nail evaluations in addition to biological tracking.
The goal is to establish when the changes initially appear, recognize the systems behind them, and identify whether they enhance or disappear over time.
The study got institutional assistance from DUCRAY Laboratories (Pierre Fabre Team), a firm specializing in skin-related and hair care items created to help manage skin and scalp problems and improve quality of life.
